AKT1 and cancer: Indeed, mTORC1 inhibitors, like rapamycin and other rapalogs, initially showed some promise in treating cancers, but their chronic administration resulted in drug resistance due to feedback activation of the PI3K/Akt pathway by mTORC2 (18, 19).